^Ad hoc announcement pursuant to Art. 53 LR
* Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the
Board of Directors
* Mathieu Simon to stand for re-election to the Board - taking on the role of
Vice-Chairman and Lead Independent Director
* André C. Muller, current CFO of Idorsia, to take over the role of CEO as of
June 13, 2024
Allschwil, Switzerland - May 21, 2024
Idorsia Ltd (SIX: IDIA) today announced changes to the Idorsia Executive
Committee (IEC) and will propose changes in membership of the Board of Directors
at the upcoming Annual General Meeting of shareholders (AGM), to be held on June
13, 2024.
Jean-Paul Clozel, 69, has decided to retire from his role as Chief Executive
Officer (CEO) of Idorsia and stand for election as Chairman of the Board of
Directors at this year's AGM. Jean-Paul has served as CEO of Idorsia since its
foundation - the result of demerging the drug discovery and early clinical
pipeline of Actelion, as part of the USD 30 billion acquisition. Jean-Paul had
previously co-founded Actelion in 1997 and went on to lead the company as CEO in
2000 when the company became publicly traded.
Jean-Paul Clozel, MD and CEO of Idorsia, commented:
"It has been an absolute privilege to serve as CEO of Actelion and Idorsia for
the past 24 years. I can think of no greater endeavor than discovering new
medicines that help patients lead better lives. I've been very fortunate to work
alongside some amazing people from all disciplines and together, we have
achieved more than I could have ever imagined when I started out in my research
career. The time is right for me to retire from the day-to-day running of
Idorsia and hand the reins over to a younger generation to lead the company
through the next phase of growth. Having devoted so much energy to Idorsia, I
want to stay engaged and support the company to realize its potential, hence me
standing for election as Chairman. I'm confident that Mathieu and I will form a
strong partnership in leading the Board. I will also be able to devote more time
to science which has always been my passion."
From June 13, 2024, André C. Muller will take on the position of CEO. André has
served as the Chief Financial Officer (CFO) of Idorsia since its foundation and
has taken the lead in the company's Business Development initiatives in recent
years. Before establishing Idorsia, André served as CFO of Actelion from 2013,
leading the company through its acquisition and playing a crucial role in the
demerger process.
Jean-Paul Clozel, commented:
"André has played a critical role in advancing Idorsia, particularly regarding
our fund-raising and business development activities. He has shown the perfect
qualities of a biotech leader; creativity, solution-oriented, resilient, a team-
player and pragmatic - all qualities that we need to successfully discover and
develop innovative drugs. Having worked with André for more than 10 years, I
have observed that, despite not being a scientist by training, he has a keen
understanding of innovative drug discovery and development. I have absolute
confidence that he is the right person to prepare the company for an exciting
future."
As a result of André becoming CEO, the role of CFO will remain an IEC member and
be taken by Arno Groenewoud, the current Head of Finance and Procurement. In
addition, Julien Gander, Group General Counsel, will become a member of the IEC.
André C. Muller, Chief Financial Officer, commented:
"I am very honored that the Board, its current Chairman, Mathieu Simon, and
Jean-Paul have put this trust in me, particularly following such a long and
successful tenure for Jean-Paul as CEO. I look forward to the challenge of
delivering on the high expectations we have for Idorsia and will work closely
with all colleagues around the globe who never fail to impress with their
commitment and expertise. I welcome Arno and Julien to the executive team.
Having worked closely with both Arno and Julien, I am convinced that their
skills and strategic thinking will be vital as the company moves towards
financial sustainability while managing multiple partnerships."
As of June 13, 2024, the IEC will consist of 5 members: André Muller, CEO;
Martine Clozel, Chief Scientific Officer; Alberto Gimona, Head of Global
Clinical Development; Arno Groenewoud, CFO; and Julien Gander, Group General
Counsel.
At this year's Annual General Meeting, the Board will propose a reduced number
of Board members for the time being. Three of the current Board members - Jörn
Aldag, Felix Ehrat, Peter Kellogg - will not stand for re-election, with only
one new member, Bart Filius, being proposed to the Board. The following Board
members will stand for re-election: Jean-Paul Clozel (proposed Chairman),
Mathieu Simon (Vice-Chairman and Lead Independent Director), Srishti Gupta,
Sophie Kornowski, and Sandy Mahatme.
Mathieu Simon, Chairman of the Board of Idorsia commented:
"This year, the Board has held numerous additional meetings to discuss and
review the various strategic initiatives. I'm very grateful for each member
contributing generously with their expertise and experience. To those not
standing for re-election, I say thank you for serving the company with
professionalism and dedication. Bart's very extensive financing, business
development, and commercial experience in the biotechnology and pharmaceutical
industry would be invaluable to Idorsia. I am completely behind the new
management team, and proposing Jean-Paul to the Chairmanship, and I look forward
to serving as Vice-Chairman and Lead Independent Director with the other members
of the Board focused on guiding Idorsia as we execute our strategy."
Following a competitive selection process, the company considers it appropriate
to invite a fresh perspective by proposing the election of Deloitte AG, Basel as
a new statutory auditor.
Notes to the editor
About Jean-Paul Clozel
Jean-Paul Clozel, 69, is a cardiologist educated in France. He furthered his
training in pharmacology and physiology at the University of Montreal, Canada,
University of California, and San Francisco. After eleven years as a clinician,
he decided to move to applied research and joined the Roche Cardiovascular Drug
Discovery group. During his 12 years at F. Hoffmann-La Roche Ltd, Jean-Paul was
responsible for the selection of the first calcium T-channel blocker and
contributed to several key research programs, such as the selection of the first
orally active renin inhibitor and the characterization of several anti-
thrombotic agents.
During his 25-year-career in cardiovascular research, Jean-Paul has published
widely in peer-reviewed medical and scientific journals. At the same time, his
passion has remained unchanged: being involved as closely as possible in
bringing innovative medicine to "his" patients. He has developed various novel
experimental models allowing for the differentiation of these drugs, work
honored with the 1997 Hoffmann-La Roche Research Prize. In 2007, he was
nominated for a professorship at the Collège de France in Paris, France (Chair
of Technical Innovation).
At the end of 1997, Jean-Paul co-founded Actelion to continue his work in
cardiovascular research and development. In April 2000, he assumed the role of
CEO when Actelion became a publicly traded company and subsequently launched
three blockbuster drugs.
With the acquisition of Actelion by Johnson & Johnson in June 2017, Jean-Paul
co-founded Idorsia, a new biopharmaceutical company that was established by
demerging the drug discovery and early clinical pipeline business from Actelion.
Idorsia is specialized in the discovery and development of small molecules to
provide innovative medicines in areas of unmet patient need.
In the first 7 years of Idorsia's existence, the company launched two innovative
drugs, one for the treatment of insomnia disorder and one for the prevention of
cerebral vasospasm following subarachnoid hemorrhage, with a third medicine on
the verge of being launch for the treatment of uncontrolled blood pressure.
Idorsia continues to perform innovative research across multiple therapeutic
areas to feed its broad and diversified drug development pipeline.
As a result of the establishment of Actelion and Idorsia, several hundred new
jobs have been created in Switzerland as well as in other European countries,
the US and Japan.
About André C. Muller
André C. Muller joined Idorsia at the time of its creation in June 2017 as Chief
Financial Officer from Actelion, where he held the same position since 2013.
Prior to joining Actelion he held various financial positions at Pierre Fabre
SA, an international pharmaceutical and dermo-cosmetic company, serving as CFO
from 2002.
André, a French citizen, has a master's degree in Business Administration from
EMLYON Business School, Lyon, France.
André also serves as a member of the Board of Directors of the listed company
Carmat SA and the unlisted company Chiron Investments AG.
About Bart Filius
Mr. Filius is the former President of Galapagos, a position he held from 2021 to
June 2023. He joined Galapagos in 2014 as Chief Financial Officer and added the
role of Chief Operating Officer in 2017. During his tenure at Galapagos, Bart
managed the substantial growth and financing of the company, including the IPO
on Nasdaq in 2015 and subsequent follow-on financing transactions. He led the
negotiations of the R&D collaboration with Gilead in 2019 and was instrumental
in the build-out of the European commercial organization. Bart is also a member
of the Board and Chairman of the Audit Committee of ProQR Therapeutics since
2019.
Prior to joining Galapagos, Mr. Filius held a variety of executive positions at
Sanofi between 2001 and 2014, including the role of Vice President, Head of
Mergers & Acquisitions, Country manager for The Netherlands and Vice President,
Chief Financial Officer for Europe. Prior to joining Sanofi, Mr. Filius was a
strategy consultant at Arthur D. Little.
Mr. Filius has an MBA degree from INSEAD, France and a bachelor's degree in
business from Nyenrode University, the Netherlands
About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a 25-year
heritage of drug discovery, a broad portfolio of innovative drugs in the
pipeline, an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North America - the
ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017
and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com (http://www.idorsia.com)
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
°
